How much funding has CRISPR raised?

CRISPR has raised $142.0M in total funding, most recently a Series B round.

Who are CRISPR's investors?

CRISPR's investors include Jerel Davis, NEA.

Where is CRISPR headquartered?

CRISPR is headquartered in Zug, Switzerland.

What industry is CRISPR in?

CRISPR operates in Biotech, Healthcare.

CRISPR

IPO

Public · Zug, Switzerland · Founded 2013 · $142.0M raised

Biotech

Healthcare

Headquarters: Zug
Employees: 201–500
Founded: 2013
Business Model: B2B

Total Funding: $142.0M
Last Round: $142.0M Series BJan 2016
Rounds: 1
Type: Public

About

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company has a diverse portfolio of product candidates spanning hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2023, its co-developed therapy CASGEVY® became the first-ever approved CRISPR-based treatment, indicated for sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics is headquartered in Zug, Switzerland, with its U.S. subsidiary and R&D operations in Boston, Massachusetts.

Summary

CRISPR is a Biotech company based in Zug, Switzerland, founded in 2013. It has raised $142.0M in total across 1 round, most recently a $142.0M Series B round in Jan 2016. Investors include Jerel Davis and NEA.